Capital Markets Event June 2026

Definitions

AAV - Adeno-associated viral vectors

AEX - Anion Exchange Chromatography

APIs - Active Pharmaceutical Ingredient

BLA/MA submission - Biologics License Application submission and Marketing Authorisation submission respectively.

CAGR - Compound Annual Growth Rate

CAR-M - Chimeric Antigen Receptor Macrophage

CAR-T - Chimeric Antigen Receptor T-cell therapy

CDMO - Contract Development and Manufacturing Organisation

CGT - Cell and gene therapy

CMC - Chemistry, Manufacturing and Controls

Contracted value of client orders - The gross value of customer orders for which the customer has signed a financial commitment, whereby any changes to agreed values will be subject to either change orders, cancellation fees or the triggering of optional/contingent contractual clauses.

CRISPR - Clustered Regularly Interspaced Short Palindromic Repeats (gene-editing technology)

DMD - Duchenne muscular dystrophy

DoE - Design of Experiments

DPO - Days Payable Outstanding

DSO - Days Sales Outstanding

DSP - Downstream Processing

E2E - End-to-End Process

Early-stage clinical trials (Phase 1 & 2) - These trials focus on assessing the safety, tolerability, and optimal dosing. For early-stage clients, OXB helps to develop robust manufacturing processes and ensures scalability. Key activities include process development, cell banking, process characterisation, and CMC (Chemistry, Manufacturing, and Controls) support. Stability studies also begin in Phase 2 to assess the viability of the therapy over time, laying the foundation for late-stage development.

GxP, GMP, GCP, GLP - GxP is a general term for Good (Anything) Practice. GMP, GCP and GLP are the practices required to conform to guidelines laid down by relevant agencies for manufacturing, clinical and laboratory activities.

IND submission - An Investigational New Drug Application

Late-stage clinical trials (Phase 3 & 4) - These trials aim to confirm the efficacy and long-term safety of gene and cell therapies in larger patient populations. These trials are centred around large-scale production and regulatory compliance, ensuring that the therapy is manufactured consistently and efficiently for broader patient access. Key CDMO activities include vector substance and product GMP manufacturing, stability studies, and QA/QP release to meet stringent regulatory standards.

LNPs - Lipid nanoparticles

LV - Lentiviral vectors

NiV - Nipah virus envelope proteins

NMD - No Major Deficiencies

NOP - Net Operating Losses

Operating EBITDA - Operating EBITDA (Earnings Before Interest, Tax, Depreciation, Amortisation, Impairment, revaluation of investments and assets at fair value through profit and loss and share based payments) is a non-GAAP measure often used as a surrogate for operational cash flow as it excludes from operating profit or loss all non-cash items, including the charge for share-based payments. However, deferred bonus share option charges are not added back to operating profits in the determination of Operating EBITDA as they may be paid in cash upon the instruction of the Remuneration Committee.

PC - Process Characterisation

PDAD - Product Development & Analytical Development

POS - Proof of Safety

PPQ - Process Performance Qualification

QA - Quality Assurance

QP - Qualified Person

Revenue backlog - The ordered gross value of CDMO revenues available to earn. The value of customer orders included in revenue backlog only includes the value of work for which the

customer has signed a financial commitment for OXB to undertake, whereby any changes to agreed values will be subject to change orders, cancellation fees or the triggering of optional/contingent contractual clauses.

SMA - Spinal Muscular Atrophy

TCR - T-cell Receptor

USP - Upstream Processing

VLPs - Virus like particles

VP - Vector product

VS - Vector substance

VSV-G - Vesicular Stomatitis Virus Glycoprotein envelope